prof. dr. Anders Wimo, dr. med., spec. druž. med.,
adjunct professor, division of Neurogeriatrics,
NVS, Karolinska Instituet
Cost effectiveness of dementia prevention
Given the present and expected future numbers of people with dementia worldwide, there is a great interest in developing strategies that can prevent, postpone or alleviate these trends.
One way is to develop disease modifying treatments for the most common type of dementia, Alzheimer´s Disease. Another way, which also can be combined with disease modifying treatments, is to focus on prevention (primary-secondary-tertiary). From epidemiology, both cardiovascular risk factors and life style factors has shown to be associated with dementia risk. It has been estimated that more than 30% of dementia cases could be avoided if a set of modifiable risk factors were controlled for. In the multidomain FINGER project, significantly positive effects on cognition and function were achieved. Thus there is a great hope that primary or secondary prevention programs could have a great impact on future numbers of people with dementia. However, such programs might be costly and we do not know the long terms effects and the long term cost effectiveness of such programs. This presentation with highlight these issues, both from methodological and result focussed viewpoints.